Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

3(60.0%)

N/A

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 3(3)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06122584Phase 3Recruiting

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Role: lead

NCT04742361Phase 3Completed

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Role: lead

NCT04487847Phase 1Completed

18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

Role: collaborator

NCT05422105Unknown

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

Role: collaborator

NCT04102553Phase 3Completed

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Role: lead

NCT04239742Not ApplicableUnknown

F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer

Role: collaborator

All 6 trials loaded